The US Food and Drug Administration (FDA) has launched a new programme aimed at accelerating the development of potential treatments for Covid-19 infection.
Under the Coronavirus Treatment Acceleration Program (CTAP), FDA is working to quickly bring therapies to patients. Furthermore, the agency is supporting research to validate the safety and effectiveness of these Covid-19 treatments.
Commenting on the programme, US Department of Health & Human Services secretary Alex Azar said: “The FDA is announcing a new, comprehensive public-private approach to bring coronavirus treatments to market as fast as possible. “As part of this new programme, the FDA is cutting red tape, redeploying staff and working day and night to review requests from